Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.35 |
| ▸ | LIPE | Q05469 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30907260 | 0.82 | DGAT1 (0.37) | DGAT1UCHL1LIPEUSP30HIF1A | |
| SCHEMBL20520117 | 0.77 | FFAR1 (0.33) | UCHL1GSK3AGSK3B | |
| SCHEMBL22445348 | 0.76 | LPL (0.33) | UCHL1GSK3AGSK3B | |
| SCHEMBL29653311 | 0.76 | LIPE (0.40) | DGAT1UCHL1LIPE | |
| SCHEMBL9943204 | 0.76 | LIPE (0.40) | DGAT1UCHL1LIPE | |
| SCHEMBL28360858 | 0.75 | DGAT1 (0.35) | DGAT1UCHL1LIPEUSP30HIF1A | |
| SCHEMBL19949147 | 0.74 | GSK3A (0.32) | DGAT1UCHL1LIPEUSP30GSK3A | |
| SCHEMBL24456349 | 0.74 | RECQL (0.40) | DGAT1LIPESMN1; SMN2 | |
| SCHEMBL29652727 | 0.74 | RECQL (0.40) | DGAT1LIPESMN1; SMN2 | |
| SCHEMBL24667122 | 0.72 | UCHL1 (0.36) | DGAT1UCHL1LIPEUSP30HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | DGAT1 4084/4885UCHL1 4116/4885PRMT5 2301/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | DGAT1 4059/4885UCHL1 4075/4885PRMT5 2094/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | DGAT1 4084/4885UCHL1 4116/4885PRMT5 2301/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | DGAT1 4059/4885UCHL1 4075/4885PRMT5 2094/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | DGAT1 4059/4885UCHL1 4075/4885PRMT5 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.